🔗 Share this article

As America undertakes sweeping changes to its immunization schedules, one figure has emerged somewhat surprisingly: Høeg, a US-based sports medicine doctor and public health researcher who first made her name by expressing skepticism about Covid vaccines throughout the global health crisis and has focused upon alleged fatalities following Covid immunization in her brief tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Vaccine Schedule

Agency leaders were set to announce major changes to the pediatric vaccination calendar in December, aligning the US with Denmark’s national calendar, according to reports – a significant shift that would put the US at odds with much of the international standard with little proof for improved outcomes. This reveal has been postponed until the next year.

Instead of the director of the vaccine center, Høeg is set to speak at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to lead the office this calendar year.

Consolidating Power at the Agency

This interim role could signify a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has often pushed for ending some childhood immunization guidelines in the US in order to be more in line with Denmark, a country with nationalized medicine and a number of inhabitants approximately the size of Wisconsin’s.

So far comments, she has kept her attention on vaccination policy – traditionally the domain of Prasad, director of the FDA’s CBER – as opposed to medication approval.

Concerns Over Expertise

Høeg has little discernible track record in medication creation, approval processes or administrative roles, which has been typical for former directors of the biologics center. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in running a large organization. She lacks background in industry regulation.”

Previous commissioners of the center would “understand regulatory frameworks and the science of medication creation”, said a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that previous people who ran the center have had.”

This division has an enormous workload at the FDA, the former commissioner pointed out.

“Everybody just pays attention on the new drug program, but the generic drug division clears thousands of generic medications. There’s a biosimilars program, over-the-counter program and more, and all of those need to be looked after,” Woodcock noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a significant management element to the role, which manages over 5,000 employees. “It is a massive management job, if you execute it properly,” the former official concluded.

Agency Reaction and Contentious Policies

When asked about inquiries about Høeg’s qualifications and whether this assignment indicates greater collaboration among FDA leaders on vaccines, a representative responded that the “inquiries are based on flawed premises”.

“Her experience matches the duties of her role,” the representative stated, noting the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg takes over the agency head's recently launched priority voucher program, a controversial one-day medication authorization process that allegedly worried her predecessors. “By what process are these drugs being selected for this expedited pathway? Who makes the decisions?” Dr. Howard questioned. “There’s a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards more relaxed rules of all drugs, except for shots.”

Established History on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if concerning, past, critics have noted. She authored a analysis using unconfirmed volunteer-provided data to assess the frequency of myocarditis after COVID-19 immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccines are more dangerous than they are.

Part of her “wish list” for the incoming government encompassed changing guidelines for new vaccines and discontinuing “unnecessary” immunizations, she stated following the vote on a podcast. At the FDA, Høeg has according to sources floated the idea of excluding adolescent males from receiving COVID-19 vaccinations.

“She is an complete true believer who starts off with her preconceived notions and works backwards to retrofit the evidence in a extremely misleading, untruthful fashion,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|